The Prevalence of Epstein-Barr Virus in Normal, Premalignant, and Malignant Uterine Cervical Samples in Iran
Abstract Introduction: It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV in cervical cancer samples in comparison to premalignant and normal groups. In this regard, this study aimed to investigate the prev...
Saved in:
| Published in | Intervirology Vol. 67; no. 1; pp. 64 - 71 |
|---|---|
| Main Authors | , , |
| Format | Journal Article |
| Language | English |
| Published |
Basel, Switzerland
S. Karger AG
15.04.2024
Karger Publishers |
| Subjects | |
| Online Access | Get full text |
| ISSN | 0300-5526 1423-0100 1423-0100 |
| DOI | 10.1159/000538734 |
Cover
| Abstract | Abstract
Introduction: It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV in cervical cancer samples in comparison to premalignant and normal groups. In this regard, this study aimed to investigate the prevalence of EBV in cervical samples. Methods: In total, 364 samples from 179 healthy subjects, 124 women with premalignant lesions, and 61 patients with cervical cancer were investigated using nested-PCR. Results: The mean age ± SE was 54.1 ± 13.4 in women with cervical cancer, 36.1 ± 9.4 among women with premalignant lesions, and 36.6 ± 11.5 in healthy individuals. In total, 290 out of 364 samples were human papillomavirus (HPV) positive and the following HPV genotypes were detected among them: HPV 16/18 was found in 43.1%, 23.9%, and 65.5% of normal, premalignant, and malignant samples, respectively, and other high-risk types were detected in 56.9% of normal, 76.1% of premalignant, and 34.5% of malignant samples. The prevalence of EBV was found to be 9.8%, 2.4%, and 2.8% in cervical cancer, premalignant lesions, and normal specimens, respectively, and the difference was statistically significant (p = 0.028). The overall frequency of coinfection between EBV and HPV was shown to be 3.6%. The coinfection was more prevalent among HPV 16/18-infected samples than other high-risk HPVs (6.6 vs. 2.9%) although the difference was not reached a statistically significant difference (p = 0.23). Conclusion: Our findings indicated that EBV could play an important role as a cofactor in the progression of cervical cancer. However, future studies with larger sample sizes and the expression analysis of EBV transcripts or proteins are mandatory. |
|---|---|
| AbstractList | Introduction: It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV in cervical cancer samples in comparison to premalignant and normal groups. In this regard, this study aimed to investigate the prevalence of EBV in cervical samples. Methods: In total, 364 samples from 179 healthy subjects, 124 women with premalignant lesions, and 61 patients with cervical cancer were investigated using nested-PCR. Results: The mean age ± SE was 54.1 ± 13.4 in women with cervical cancer, 36.1 ± 9.4 among women with premalignant lesions, and 36.6 ± 11.5 in healthy individuals. In total, 290 out of 364 samples were human papillomavirus (HPV) positive and the following HPV genotypes were detected among them: HPV 16/18 was found in 43.1%, 23.9%, and 65.5% of normal, premalignant, and malignant samples, respectively, and other high-risk types were detected in 56.9% of normal, 76.1% of premalignant, and 34.5% of malignant samples. The prevalence of EBV was found to be 9.8%, 2.4%, and 2.8% in cervical cancer, premalignant lesions, and normal specimens, respectively, and the difference was statistically significant (p = 0.028). The overall frequency of coinfection between EBV and HPV was shown to be 3.6%. The coinfection was more prevalent among HPV 16/18-infected samples than other high-risk HPVs (6.6 vs. 2.9%) although the difference was not reached a statistically significant difference (p = 0.23). Conclusion: Our findings indicated that EBV could play an important role as a cofactor in the progression of cervical cancer. However, future studies with larger sample sizes and the expression analysis of EBV transcripts or proteins are mandatory. Introduction: It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV in cervical cancer samples in comparison to premalignant and normal groups. In this regard, this study aimed to investigate the prevalence of EBV in cervical samples. Methods: In total, 364 samples from 179 healthy subjects, 124 women with premalignant lesions, and 61 patients with cervical cancer were investigated using nested PCR. Results: The mean age ± SE was 54.1 ± 13.4 in women with cervical cancer, 36.1 ± 9.4 among women with premalignant lesions and 36.6 ± 11.5 in healthy individuals. In total, 290 out of 364 samples were HPV positive and the following HPV genotypes were detected among them: HPV 16/18 was found in 43.1%, 23.9%, and 65.5%of normal, premalignant, and malignant samples, respectively, and other high-risk types were detected in 56.9% of normal, 76.1% of premalignant, and 34.5% of malignant samples. The prevalence of EBV was found to be 9.8%, 2.4%, and 2.8% in cervical cancer, premalignant lesions, and normal specimens, respectively, and the difference was statistically significant (P=0.028). The overall frequency of co-infection between EBV and HPV was shown to be 3.6%. The co-infection was more prevalent among HPV 16/18-infected samples than other high-risk HPVs (6.6% vs. 2.9%) although the difference was not reached a statistically significant difference (P=0.23). Conclusion: Our findings indicated that EBV could play an important role as a cofactor in the progression of cervical cancer. However, future studies with larger sample sizes and the expression analysis of EBV transcripts or proteins are mandatory. It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV in cervical cancer samples in comparison to premalignant and normal groups. In this regard, this study aimed to investigate the prevalence of EBV in cervical samples.INTRODUCTIONIt is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV in cervical cancer samples in comparison to premalignant and normal groups. In this regard, this study aimed to investigate the prevalence of EBV in cervical samples.In total, 364 samples from 179 healthy subjects, 124 women with premalignant lesions, and 61 patients with cervical cancer were investigated using nested-PCR.METHODSIn total, 364 samples from 179 healthy subjects, 124 women with premalignant lesions, and 61 patients with cervical cancer were investigated using nested-PCR.The mean age ± SE was 54.1 ± 13.4 in women with cervical cancer, 36.1 ± 9.4 among women with premalignant lesions, and 36.6 ± 11.5 in healthy individuals. In total, 290 out of 364 samples were human papillomavirus (HPV) positive and the following HPV genotypes were detected among them: HPV 16/18 was found in 43.1%, 23.9%, and 65.5% of normal, premalignant, and malignant samples, respectively, and other high-risk types were detected in 56.9% of normal, 76.1% of premalignant, and 34.5% of malignant samples. The prevalence of EBV was found to be 9.8%, 2.4%, and 2.8% in cervical cancer, premalignant lesions, and normal specimens, respectively, and the difference was statistically significant (p = 0.028). The overall frequency of coinfection between EBV and HPV was shown to be 3.6%. The coinfection was more prevalent among HPV 16/18-infected samples than other high-risk HPVs (6.6 vs. 2.9%) although the difference was not reached a statistically significant difference (p = 0.23).RESULTSThe mean age ± SE was 54.1 ± 13.4 in women with cervical cancer, 36.1 ± 9.4 among women with premalignant lesions, and 36.6 ± 11.5 in healthy individuals. In total, 290 out of 364 samples were human papillomavirus (HPV) positive and the following HPV genotypes were detected among them: HPV 16/18 was found in 43.1%, 23.9%, and 65.5% of normal, premalignant, and malignant samples, respectively, and other high-risk types were detected in 56.9% of normal, 76.1% of premalignant, and 34.5% of malignant samples. The prevalence of EBV was found to be 9.8%, 2.4%, and 2.8% in cervical cancer, premalignant lesions, and normal specimens, respectively, and the difference was statistically significant (p = 0.028). The overall frequency of coinfection between EBV and HPV was shown to be 3.6%. The coinfection was more prevalent among HPV 16/18-infected samples than other high-risk HPVs (6.6 vs. 2.9%) although the difference was not reached a statistically significant difference (p = 0.23).Our findings indicated that EBV could play an important role as a cofactor in the progression of cervical cancer. However, future studies with larger sample sizes and the expression analysis of EBV transcripts or proteins are mandatory.CONCLUSIONOur findings indicated that EBV could play an important role as a cofactor in the progression of cervical cancer. However, future studies with larger sample sizes and the expression analysis of EBV transcripts or proteins are mandatory. Abstract Introduction: It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV in cervical cancer samples in comparison to premalignant and normal groups. In this regard, this study aimed to investigate the prevalence of EBV in cervical samples. Methods: In total, 364 samples from 179 healthy subjects, 124 women with premalignant lesions, and 61 patients with cervical cancer were investigated using nested-PCR. Results: The mean age ± SE was 54.1 ± 13.4 in women with cervical cancer, 36.1 ± 9.4 among women with premalignant lesions, and 36.6 ± 11.5 in healthy individuals. In total, 290 out of 364 samples were human papillomavirus (HPV) positive and the following HPV genotypes were detected among them: HPV 16/18 was found in 43.1%, 23.9%, and 65.5% of normal, premalignant, and malignant samples, respectively, and other high-risk types were detected in 56.9% of normal, 76.1% of premalignant, and 34.5% of malignant samples. The prevalence of EBV was found to be 9.8%, 2.4%, and 2.8% in cervical cancer, premalignant lesions, and normal specimens, respectively, and the difference was statistically significant (p = 0.028). The overall frequency of coinfection between EBV and HPV was shown to be 3.6%. The coinfection was more prevalent among HPV 16/18-infected samples than other high-risk HPVs (6.6 vs. 2.9%) although the difference was not reached a statistically significant difference (p = 0.23). Conclusion: Our findings indicated that EBV could play an important role as a cofactor in the progression of cervical cancer. However, future studies with larger sample sizes and the expression analysis of EBV transcripts or proteins are mandatory. It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV in cervical cancer samples in comparison to premalignant and normal groups. In this regard, this study aimed to investigate the prevalence of EBV in cervical samples. In total, 364 samples from 179 healthy subjects, 124 women with premalignant lesions, and 61 patients with cervical cancer were investigated using nested-PCR. The mean age ± SE was 54.1 ± 13.4 in women with cervical cancer, 36.1 ± 9.4 among women with premalignant lesions, and 36.6 ± 11.5 in healthy individuals. In total, 290 out of 364 samples were human papillomavirus (HPV) positive and the following HPV genotypes were detected among them: HPV 16/18 was found in 43.1%, 23.9%, and 65.5% of normal, premalignant, and malignant samples, respectively, and other high-risk types were detected in 56.9% of normal, 76.1% of premalignant, and 34.5% of malignant samples. The prevalence of EBV was found to be 9.8%, 2.4%, and 2.8% in cervical cancer, premalignant lesions, and normal specimens, respectively, and the difference was statistically significant (p = 0.028). The overall frequency of coinfection between EBV and HPV was shown to be 3.6%. The coinfection was more prevalent among HPV 16/18-infected samples than other high-risk HPVs (6.6 vs. 2.9%) although the difference was not reached a statistically significant difference (p = 0.23). Our findings indicated that EBV could play an important role as a cofactor in the progression of cervical cancer. However, future studies with larger sample sizes and the expression analysis of EBV transcripts or proteins are mandatory. |
| Author | Jalilvand, Somayeh Chavoshpour-Mamaghani, Sara Shoja, Zabihollah |
| Author_xml | – sequence: 1 givenname: Sara surname: Chavoshpour-Mamaghani fullname: Chavoshpour-Mamaghani, Sara – sequence: 2 givenname: Zabihollah surname: Shoja fullname: Shoja, Zabihollah – sequence: 3 givenname: Somayeh surname: Jalilvand fullname: Jalilvand, Somayeh email: *Somayeh Jalilvand, sjalilvand@tums.ac.ir |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/38621370$$D View this record in MEDLINE/PubMed |
| BookMark | eNpt0kFv0zAUwHELDbFucOCOkCUuIC3wHMdOckJQDag0BhIdV-vFee48Eic4aSW-PdnSVUziZNn--e-DfcKOQheIsecC3gqhyncAoGSRy-wRW4gslQkIgCO2AAmQKJXqY3YyDDcTk0LCE3YsC50KmcOCNetr4t8j7bChYIl3jp_3w0g-JB8xRv7Tx-3AfeCXXWyxObu10-g3AcN4xjHU_Ov9lF-NFH0gvqS48xYb_gPbvqG786uI4Sl77LAZ6Nl-PGVXn87Xyy_JxbfPq-WHi8RKrbOkyFRlNbhSoCaFlVK5SyGlAoSsi0xqqaSyerLOEWjKnQRdOGtRQVrlmTxlq7lbd3hj-uhbjH9Mh97cLXRxYzCO3jZkSsxLrEDoNHfZFCokiTQv60rZTJZ5PbXez61-W7VUWwpjxOZB9OFO8Ndm0-2MEKkSOsunwut9IXa_tzSMpvWDpabBQN12MBJkWYCWmZjoy38vO9xy_14TeDMDG7thiOQORIC5_Qvm8Bcm-2q2vzBuKB7k6nI9C9PXblIv_qv2kb-v4rkf |
| Cites_doi | 10.1002/(sici)1097-0215(20000101)85:1%3c35::aid-ijc6%3e3.0.co;2-a 10.1016/j.jcv.2015.10.015 10.1016/S2352-3018(17)30149-2 10.1111/j.1525-1438.2005.15222.x 10.31557/APJCP.2020.21.5.1459 10.3389/fonc.2018.00250 10.3322/caac.21660 10.1086/342596 10.18388/abp.2009_2466 10.1371/journal.pone.0180841 10.1056/NEJM200008173430707 10.1007/s00404-013-3122-3 10.1016/j.virusres.2011.09.027 10.1186/s13000-015-0283-3 10.3390/pathogens9090685 10.1016/s1470-2045(09)70096-8 10.3389/fcimb.2021.703259 10.1016/j.cell.2011.02.013 10.1097/00019606-200112000-00009 10.1016/j.virusres.2016.11.002 10.1056/NEJMoa021641 10.1016/j.ygyno.2012.11.032 10.1128/microbiolspec.DMIH2-0011-2015 10.1590/S1517-83822012000200039 10.1002/jmv.24908 10.1128/JVI.01718-16 10.1002/jmv.23596 10.1007/s00203-019-01747-4 10.1016/j.vaccine.2012.06.083 10.1016/j.ypmed.2011.08.017 10.1002/ijc.25396 10.1016/j.vaccine.2012.05.089 10.1016/j.ygyno.2017.10.005 10.1016/j.bpobgyn.2017.08.015 10.1002/1097-0142(19930915)72:6%3c1946::aid-cncr2820720625%3e3.0.co;2-7 10.1016/s0015-0282(03)00370-4 10.1016/0306-9877(91)90236-r 10.1016/j.exger.2007.01.005 |
| ContentType | Journal Article |
| Copyright | 2024 The Author(s). Published by S. Karger AG, Basel 2024 The Author(s). Published by S. Karger AG, Basel. 2024 The Author(s). Published by S. Karger AG, Basel 2024 |
| Copyright_xml | – notice: 2024 The Author(s). Published by S. Karger AG, Basel – notice: 2024 The Author(s). Published by S. Karger AG, Basel. – notice: 2024 The Author(s). Published by S. Karger AG, Basel 2024 |
| DBID | M-- AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1159/000538734 |
| DatabaseName | Karger Open Journals (Free, activated by CARLI) CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | CrossRef MEDLINE - Academic MEDLINE |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database – sequence: 4 dbid: M-- name: Karger Open Access Journals url: https://www.karger.com/OpenAccess sourceTypes: Enrichment Source Publisher |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Biology |
| DocumentTitleAlternate | The Prevalence of Epstein-Barr Virus in Cervical Samples |
| EISSN | 1423-0100 |
| EndPage | 71 |
| ExternalDocumentID | oai_doaj_org_article_9a79ab01627f47f383e1279db5c4397d PMC11251647 38621370 10_1159_000538734 538734 |
| Genre | Journal Article |
| GeographicLocations | Iran |
| GeographicLocations_xml | – name: Iran |
| GroupedDBID | --- -~X 0~B 29J 326 36B 3O. 4.4 5GY 5RE 7X7 8UI AAYIC ABBTS ABPAZ ABUWG ABWCG ACGFS ACGOD ACPRK ACPSR ADBBV ADFRT AENEX AEYAO AHFRZ AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BBNVY BENPR BHPHI BPHCQ CS3 DU5 DWQXO E0A EBS EMB EMOBN F5P FB. FYUFA GNUQQ GROUPED_DOAJ HCIFZ HZ~ IAO IHR INH ITC IY7 KUZGX L7B M-- M1P M7P N9A O1H O9- OK1 RKO SV3 UJ6 AAYXX CITATION .GJ 0~5 30W 34G 39C 3O- 53G 88E 88I 8AF 8AO 8FE 8FH 8FI 8FJ ABJNI ACQXL ADAGL AFFNX AFJJK AFKRA AFSIO AI. AIOBO BVXVI CAG CCPQU CGR COF CUY CVF CYUIP ECM EIF EJD HMCUK LK8 M2P NPM OHT PHGZT PQQKQ PROAC PSQYO RIG RXVBD S0X UKHRP VH1 ZGI ZXP 7X8 5PM |
| ID | FETCH-LOGICAL-c3664-845bc60f91a6e5ab557f202e8013d84363535c6366ffe06e7f3068fcca502b743 |
| IEDL.DBID | M-- |
| ISSN | 0300-5526 1423-0100 |
| IngestDate | Wed Aug 27 01:24:45 EDT 2025 Thu Aug 21 18:32:57 EDT 2025 Fri Sep 05 10:58:35 EDT 2025 Thu Apr 03 07:05:52 EDT 2025 Wed Aug 20 07:41:34 EDT 2025 Fri Apr 25 05:07:44 EDT 2025 Fri Apr 25 05:07:19 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Human papillomavirus Cervical cancer Genotypes Epstein‐Barr virus |
| Language | English |
| License | This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC). Usage and distribution for commercial purposes requires written permission. https://creativecommons.org/licenses/by-nc/4.0 2024 The Author(s). Published by S. Karger AG, Basel. This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c3664-845bc60f91a6e5ab557f202e8013d84363535c6366ffe06e7f3068fcca502b743 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| OpenAccessLink | https://karger.com/doi/10.1159/000538734 |
| PMID | 38621370 |
| PQID | 3039806341 |
| PQPubID | 23479 |
| PageCount | 8 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_9a79ab01627f47f383e1279db5c4397d crossref_primary_10_1159_000538734 pubmedcentral_primary_oai_pubmedcentral_nih_gov_11251647 proquest_miscellaneous_3039806341 karger_primary_538734 pubmed_primary_38621370 |
| PublicationCentury | 2000 |
| PublicationDate | 2024-04-15 |
| PublicationDateYYYYMMDD | 2024-04-15 |
| PublicationDate_xml | – month: 04 year: 2024 text: 2024-04-15 day: 15 |
| PublicationDecade | 2020 |
| PublicationPlace | Basel, Switzerland |
| PublicationPlace_xml | – name: Basel, Switzerland – name: Switzerland |
| PublicationTitle | Intervirology |
| PublicationTitleAlternate | Intervirology |
| PublicationYear | 2024 |
| Publisher | S. Karger AG Karger Publishers |
| Publisher_xml | – name: S. Karger AG – name: Karger Publishers |
| References | Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. Kapranos N, Petrakou E, Anastasiadou C, Kotronias D. Detection of herpes simplex virus, cytomegalovirus, and Epstein-Barr virus in the semen of men attending an infertility clinic. Fertil Steril. 2003;79(Suppl 3):1566–70. Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481–92. McCormick TM, Canedo NH, Furtado YL, Silveira FA, de Lima RJ, Rosman AD, . Association between human papillomavirus and Epstein: barr virus DNA and gene promoter methylation of RB1 and CDH1 in the cervical lesions: a transversal study. Diagn Pathol. 2015;10:59. International Agency for Research on CancerGLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020. 2020. National report of the National Cancer Registry Program in Iran. 2017. Munoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsague X, Shah KV, . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27. Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, . The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–70. Crawford DH, Swerdlow AJ, Higgins C, McAulay K, Harrison N, Williams H, . Sexual history and epstein-barr virus infection. J Infect Dis. 2002;186(6):731–6. Kovachev SM. Cervical cancer and vaginal microbiota changes. Arch Microbiol. 2020;202(2):323–7. Kahla S, Oueslati S, Achour M, Kochbati L, Chanoufi MB, Maalej M, . Correlation between ebv co-infection and HPV16 genome integrity in Tunisian cervical cancer patients. Braz J Microbiol. 2012;43(2):744–53. Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P; ART and HPV Review Group. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(1):e45–58. Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 2011;53(Suppl 1):S12–21. Joharinia N, Faghihinejad S, Seyedi K, Farhadi A, Hosseini SY, Safaei A, . Co-Existing of HSV1/2 or EBV infection with the presence of high-risk HPV DNA in cervical lesions in the southwest of Iran. Asian Pac J Cancer Prev. 2020;21(5):1459–64. Feng M, Duan R, Gao Y, Zhang H, Qiao Y, Li Q, . Role of epstein-barr virus and human papillomavirus coinfection in cervical intraepithelial neoplasia in Chinese women living with HIV. Front Cell Infect Microbiol. 2021;11:703259. Jalilvand S, Tornesello ML, Buonaguro FM, Buonaguro L, Naraghi ZS, Shoja Z, . Molecular epidemiology of human herpesvirus 8 variants in Kaposi’s sarcoma from Iranian patients. Virus Res. 2012 2/2012;163(2):644–9. Al-Thawadi H, Ghabreau L, Aboulkassim T, Yasmeen A, Vranic S, Batist G, . Co-incidence of epstein-barr virus and high-risk human papillomaviruses in cervical cancer of Syrian women. Front Oncol. 2018;8:250–0. Blanco R, Carrillo-Beltrán D, Osorio JC, Calaf GM, Aguayo F. Role of epstein-barr virus and human papillomavirus coinfection in cervical cancer: epidemiology, mechanisms and perspectives. Pathogens. 2020;9(9):685. Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–35. Seo SS, Kim WH, Song YS, Kim SH, Kim JW, Park NH, . Epstein-Barr virus plays little role in cervical carcinogenesis in Korean women. Int J Gynecol Cancer. 2005;15(2):312–8. Hilton DA, Brown LJR, Pringle JH, Nandha H. Absence of epstein – barr virus in carcinoma of the cervix. Cancer. 1993;72(6):1946–8. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. Wang LW, Jiang S, Gewurz BE. Epstein-Barr virus LMP1-mediated oncogenicity. J Virol. 2017;91(21):e01718–16. de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13. Thomasini RL, Pereira DS, Pereira FSM, Mateo EC, Mota TN, Guimarães GG, . Aged-associated cytomegalovirus and Epstein-Barr virus reactivation and cytomegalovirus relationship with the frailty syndrome in older women. PLoS One. 2017;12(7):e0180841. Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, . Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30 Suppl 5(0 5):F24–33. Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, . A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009 4/2009;10(4):321–2. Nowalk A, Green M. Epstein-Barr virus. Microbiol Spectr. 2016;4(3). Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, Glaser R. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol. 2007;42(6):563–70. Sato Y, Sugie R, Tsuchiya B, Kameya T, Natori M, Mukai K. Comparison of the DNA extraction methods for polymerase chain reaction amplification from formalin-fixed and paraffin-embedded tissues. Diagn Mol Pathol. 2001;10(4):265–71. Shimabuku T, Tamanaha A, Kitamura B, Tanabe Y, Tawata N, Ikehara F, . Dual expression of Epstein-Barr virus, latent membrane protein-1 and human papillomavirus-16 E6 transform primary mouse embryonic fibroblasts through NF-κB signaling. Int J Clin Exp Pathol. 2014;7(5):1920–34. Guidry JT, Scott RS. The interaction between human papillomavirus and other viruses. Virus Res. 2017;231:139–47. Silva J, Cerqueira F, Medeiros R. Chlamydia trachomatis infection: implications for HPV status and cervical cancer. Arch Gynecol Obstet. 2014;289(4):715–23. Aromseree S, Pientong C, Swangphon P, Chaiwongkot A, Patarapadungkit N, Kleebkaow P, . Possible contributing role of Epstein-Barr virus (EBV) as a cofactor in human papillomavirus (HPV)-associated cervical carcinogenesis. J Clin Virol. 2015;73:70–6. Santos NBM, Villanova FE, Andrade PM, Ribalta J, Focchi J, Otsuka AY, . Epstein-Barr virus detection in invasive and pre-invasive lesions of the uterine cervix. Oncol Rep. 2009;21(2):403–5. de Lima MAP, Neto PJN, Lima LPM, Gonçalves Júnior J, Teixeira Junior AG, Teodoro IPP, . Association between Epstein-Barr virus (EBV) and cervical carcinoma: a meta-analysis. Gynecol Oncol. 2018;148(2):317–28. Marinho-Dias J, Ribeiro J, Monteiro P, Loureiro J, Baldaque I, Medeiros R, . Characterization of cytomegalovirus and epstein-barr virus infection in cervical lesions in Portugal. J Med Virol. 2013;85(8):1409–13. Koskela P, Anttila T, Bjørge T, Brunsvig A, Dillner J, Hakama M, . Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer. 2000;85(1):35–9. Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, H Rashidi B, . Epidemiology of cervical cancer and human papilloma virus infection among Iranian women: analyses of national data and systematic review of the literature. Gynecol Oncol. 2013;128(2):277–81. Szostek S, Zawilinska B, Kopec J, Kosz-Vnenchak M. Herpesviruses as possible cofactors in HPV-16-related oncogenesis. Acta Biochim Pol. 2009;56(2):337–42. Wong SY, Sewell HF, MacGregor JE, Walker F. Epstein-Barr virus--a possible missing link in the initiation of cervical carcinogenesis. Med Hypotheses. 1991;35(3):219–22. Heydari N, Oskouee MA, Vaezi T, Shoja Z, Esmaeili HA, Hamkar R, . Type‐specific human papillomavirus prevalence in cervical intraepithelial neoplasia and cancer in Iran. J Med Virol. 2018;90(1):172–6. ref13 ref35 ref12 ref34 ref15 ref37 ref14 ref36 ref31 ref30 ref11 ref33 ref10 ref32 ref2 ref1 ref17 ref16 ref38 ref19 ref18 ref24 ref23 ref26 ref25 ref20 ref22 ref21 ref28 ref27 ref29 ref8 ref7 ref9 ref4 ref3 ref6 ref5 |
| References_xml | – reference: Seo SS, Kim WH, Song YS, Kim SH, Kim JW, Park NH, . Epstein-Barr virus plays little role in cervical carcinogenesis in Korean women. Int J Gynecol Cancer. 2005;15(2):312–8. – reference: Szostek S, Zawilinska B, Kopec J, Kosz-Vnenchak M. Herpesviruses as possible cofactors in HPV-16-related oncogenesis. Acta Biochim Pol. 2009;56(2):337–42. – reference: International Agency for Research on CancerGLOBOCAN 2020: estimated cancer incidence, mortality and prevalence worldwide in 2020. 2020. – reference: Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646–74. – reference: Sato Y, Sugie R, Tsuchiya B, Kameya T, Natori M, Mukai K. Comparison of the DNA extraction methods for polymerase chain reaction amplification from formalin-fixed and paraffin-embedded tissues. Diagn Mol Pathol. 2001;10(4):265–71. – reference: Kelly H, Weiss HA, Benavente Y, de Sanjose S, Mayaud P; ART and HPV Review Group. Association of antiretroviral therapy with high-risk human papillomavirus, cervical intraepithelial neoplasia, and invasive cervical cancer in women living with HIV: a systematic review and meta-analysis. Lancet HIV. 2018;5(1):e45–58. – reference: Wong SY, Sewell HF, MacGregor JE, Walker F. Epstein-Barr virus--a possible missing link in the initiation of cervical carcinogenesis. Med Hypotheses. 1991;35(3):219–22. – reference: Wang LW, Jiang S, Gewurz BE. Epstein-Barr virus LMP1-mediated oncogenicity. J Virol. 2017;91(21):e01718–16. – reference: Stowe RP, Kozlova EV, Yetman DL, Walling DM, Goodwin JS, Glaser R. Chronic herpesvirus reactivation occurs in aging. Exp Gerontol. 2007;42(6):563–70. – reference: Kovachev SM. Cervical cancer and vaginal microbiota changes. Arch Microbiol. 2020;202(2):323–7. – reference: Li N, Franceschi S, Howell-Jones R, Snijders PJ, Clifford GM. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer. 2011;128(4):927–35. – reference: Crawford DH, Swerdlow AJ, Higgins C, McAulay K, Harrison N, Williams H, . Sexual history and epstein-barr virus infection. J Infect Dis. 2002;186(6):731–6. – reference: Tota JE, Chevarie-Davis M, Richardson LA, Devries M, Franco EL. Epidemiology and burden of HPV infection and related diseases: implications for prevention strategies. Prev Med. 2011;53(Suppl 1):S12–21. – reference: Aromseree S, Pientong C, Swangphon P, Chaiwongkot A, Patarapadungkit N, Kleebkaow P, . Possible contributing role of Epstein-Barr virus (EBV) as a cofactor in human papillomavirus (HPV)-associated cervical carcinogenesis. J Clin Virol. 2015;73:70–6. – reference: Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, . Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30 Suppl 5(0 5):F24–33. – reference: Hilton DA, Brown LJR, Pringle JH, Nandha H. Absence of epstein – barr virus in carcinoma of the cervix. Cancer. 1993;72(6):1946–8. – reference: Kahla S, Oueslati S, Achour M, Kochbati L, Chanoufi MB, Maalej M, . Correlation between ebv co-infection and HPV16 genome integrity in Tunisian cervical cancer patients. Braz J Microbiol. 2012;43(2):744–53. – reference: Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, . The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–70. – reference: Blanco R, Carrillo-Beltrán D, Osorio JC, Calaf GM, Aguayo F. Role of epstein-barr virus and human papillomavirus coinfection in cervical cancer: epidemiology, mechanisms and perspectives. Pathogens. 2020;9(9):685. – reference: Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, . Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–49. – reference: McCormick TM, Canedo NH, Furtado YL, Silveira FA, de Lima RJ, Rosman AD, . Association between human papillomavirus and Epstein: barr virus DNA and gene promoter methylation of RB1 and CDH1 in the cervical lesions: a transversal study. Diagn Pathol. 2015;10:59. – reference: Shimabuku T, Tamanaha A, Kitamura B, Tanabe Y, Tawata N, Ikehara F, . Dual expression of Epstein-Barr virus, latent membrane protein-1 and human papillomavirus-16 E6 transform primary mouse embryonic fibroblasts through NF-κB signaling. Int J Clin Exp Pathol. 2014;7(5):1920–34. – reference: Joharinia N, Faghihinejad S, Seyedi K, Farhadi A, Hosseini SY, Safaei A, . Co-Existing of HSV1/2 or EBV infection with the presence of high-risk HPV DNA in cervical lesions in the southwest of Iran. Asian Pac J Cancer Prev. 2020;21(5):1459–64. – reference: Cohen JI. Epstein-Barr virus infection. N Engl J Med. 2000;343(7):481–92. – reference: Jalilvand S, Tornesello ML, Buonaguro FM, Buonaguro L, Naraghi ZS, Shoja Z, . Molecular epidemiology of human herpesvirus 8 variants in Kaposi’s sarcoma from Iranian patients. Virus Res. 2012 2/2012;163(2):644–9. – reference: Thomasini RL, Pereira DS, Pereira FSM, Mateo EC, Mota TN, Guimarães GG, . Aged-associated cytomegalovirus and Epstein-Barr virus reactivation and cytomegalovirus relationship with the frailty syndrome in older women. PLoS One. 2017;12(7):e0180841. – reference: National report of the National Cancer Registry Program in Iran. 2017. – reference: Munoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsague X, Shah KV, . Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348(6):518–27. – reference: Nowalk A, Green M. Epstein-Barr virus. Microbiol Spectr. 2016;4(3). – reference: Heydari N, Oskouee MA, Vaezi T, Shoja Z, Esmaeili HA, Hamkar R, . Type‐specific human papillomavirus prevalence in cervical intraepithelial neoplasia and cancer in Iran. J Med Virol. 2018;90(1):172–6. – reference: de Lima MAP, Neto PJN, Lima LPM, Gonçalves Júnior J, Teixeira Junior AG, Teodoro IPP, . Association between Epstein-Barr virus (EBV) and cervical carcinoma: a meta-analysis. Gynecol Oncol. 2018;148(2):317–28. – reference: de Sanjosé S, Brotons M, Pavón MA. The natural history of human papillomavirus infection. Best Pract Res Clin Obstet Gynaecol. 2018;47:2–13. – reference: Guidry JT, Scott RS. The interaction between human papillomavirus and other viruses. Virus Res. 2017;231:139–47. – reference: Al-Thawadi H, Ghabreau L, Aboulkassim T, Yasmeen A, Vranic S, Batist G, . Co-incidence of epstein-barr virus and high-risk human papillomaviruses in cervical cancer of Syrian women. Front Oncol. 2018;8:250–0. – reference: Silva J, Cerqueira F, Medeiros R. Chlamydia trachomatis infection: implications for HPV status and cervical cancer. Arch Gynecol Obstet. 2014;289(4):715–23. – reference: Bouvard V, Baan R, Straif K, Grosse Y, Secretan B, El Ghissassi F, . A review of human carcinogens--Part B: biological agents. Lancet Oncol. 2009 4/2009;10(4):321–2. – reference: Santos NBM, Villanova FE, Andrade PM, Ribalta J, Focchi J, Otsuka AY, . Epstein-Barr virus detection in invasive and pre-invasive lesions of the uterine cervix. Oncol Rep. 2009;21(2):403–5. – reference: Kapranos N, Petrakou E, Anastasiadou C, Kotronias D. Detection of herpes simplex virus, cytomegalovirus, and Epstein-Barr virus in the semen of men attending an infertility clinic. Fertil Steril. 2003;79(Suppl 3):1566–70. – reference: Khorasanizadeh F, Hassanloo J, Khaksar N, Mohammad Taheri S, Marzaban M, H Rashidi B, . Epidemiology of cervical cancer and human papilloma virus infection among Iranian women: analyses of national data and systematic review of the literature. Gynecol Oncol. 2013;128(2):277–81. – reference: Feng M, Duan R, Gao Y, Zhang H, Qiao Y, Li Q, . Role of epstein-barr virus and human papillomavirus coinfection in cervical intraepithelial neoplasia in Chinese women living with HIV. Front Cell Infect Microbiol. 2021;11:703259. – reference: Koskela P, Anttila T, Bjørge T, Brunsvig A, Dillner J, Hakama M, . Chlamydia trachomatis infection as a risk factor for invasive cervical cancer. Int J Cancer. 2000;85(1):35–9. – reference: Marinho-Dias J, Ribeiro J, Monteiro P, Loureiro J, Baldaque I, Medeiros R, . Characterization of cytomegalovirus and epstein-barr virus infection in cervical lesions in Portugal. J Med Virol. 2013;85(8):1409–13. – ident: ref9 doi: 10.1002/(sici)1097-0215(20000101)85:1%3c35::aid-ijc6%3e3.0.co;2-a – ident: ref21 doi: 10.1016/j.jcv.2015.10.015 – ident: ref12 doi: 10.1016/S2352-3018(17)30149-2 – ident: ref19 doi: 10.1111/j.1525-1438.2005.15222.x – ident: ref22 doi: 10.31557/APJCP.2020.21.5.1459 – ident: ref31 doi: 10.3389/fonc.2018.00250 – ident: ref1 doi: 10.3322/caac.21660 – ident: ref16 doi: 10.1086/342596 – ident: ref29 doi: 10.18388/abp.2009_2466 – ident: ref38 doi: 10.1371/journal.pone.0180841 – ident: ref15 doi: 10.1056/NEJM200008173430707 – ident: ref10 doi: 10.1007/s00404-013-3122-3 – ident: ref23 doi: 10.1016/j.virusres.2011.09.027 – ident: ref32 doi: 10.1186/s13000-015-0283-3 – ident: ref35 doi: 10.3390/pathogens9090685 – ident: ref2 doi: 10.1016/s1470-2045(09)70096-8 – ident: ref28 doi: 10.3389/fcimb.2021.703259 – ident: ref33 doi: 10.1016/j.cell.2011.02.013 – ident: ref24 doi: 10.1097/00019606-200112000-00009 – ident: ref34 doi: 10.1016/j.virusres.2016.11.002 – ident: ref4 doi: 10.1056/NEJMoa021641 – ident: ref36 doi: 10.1016/j.ygyno.2012.11.032 – ident: ref17 doi: 10.1128/microbiolspec.DMIH2-0011-2015 – ident: ref26 doi: 10.1590/S1517-83822012000200039 – ident: ref25 doi: 10.1002/jmv.24908 – ident: ref30 doi: 10.1128/JVI.01718-16 – ident: ref20 doi: 10.1002/jmv.23596 – ident: ref13 doi: 10.1007/s00203-019-01747-4 – ident: ref3 doi: 10.1016/j.vaccine.2012.06.083 – ident: ref6 doi: 10.1016/j.ypmed.2011.08.017 – ident: ref5 doi: 10.1002/ijc.25396 – ident: ref7 doi: 10.1016/j.vaccine.2012.05.089 – ident: ref11 doi: 10.1016/j.ygyno.2017.10.005 – ident: ref8 doi: 10.1016/j.bpobgyn.2017.08.015 – ident: ref27 doi: 10.1002/1097-0142(19930915)72:6%3c1946::aid-cncr2820720625%3e3.0.co;2-7 – ident: ref14 doi: 10.1016/s0015-0282(03)00370-4 – ident: ref18 doi: 10.1016/0306-9877(91)90236-r – ident: ref37 doi: 10.1016/j.exger.2007.01.005 |
| SSID | ssj0003130 |
| Score | 2.3649502 |
| Snippet | Abstract
Introduction: It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher... Introduction: It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV... It is suggested that Epstein-Barr virus (EBV) may play an important role in cervical cancer development. Most studies found a higher rate of EBV in cervical... |
| SourceID | doaj pubmedcentral proquest pubmed crossref karger |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 64 |
| SubjectTerms | Adult Aged Cervix Uteri - pathology Cervix Uteri - virology DNA, Viral - genetics Epstein-Barr Virus Infections - epidemiology Epstein-Barr Virus Infections - virology Female Genotype Herpesvirus 4, Human - genetics Herpesvirus 4, Human - isolation & purification Human papillomavirus 16 - genetics Human papillomavirus 16 - isolation & purification Human papillomavirus 18 - genetics Human papillomavirus 18 - isolation & purification Humans Iran - epidemiology Middle Aged Papillomaviridae - classification Papillomaviridae - genetics Papillomaviridae - isolation & purification Papillomavirus Infections - epidemiology Papillomavirus Infections - virology Polymerase Chain Reaction Precancerous Conditions - epidemiology Precancerous Conditions - virology Prevalence Research Article Uterine Cervical Neoplasms - epidemiology Uterine Cervical Neoplasms - virology |
| SummonAdditionalLinks | – databaseName: DOAJ Directory of Open Access Journals dbid: DOA link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1NT9wwELUqJKReUEuBpoXKrXokIom_kiMgEFRiL2UrbtHEH-2qVXaV3T3w75lxkhWLKvXSU-TYcWI_x-85Gc8w9tUVTvuq1GnRFCaVQuoUIJNpEJbiWQOqWPqgfzfRN1P57UE9PAv1RTZhvXvgvuPOKjAVNChMChOkCbig8nlhKtcoS1zqaPZFGhsXU8McLHBqHvwIIV_HyHWiNEJusU900o_M85tsrru_ScyXlpLPqOf6DdsbNCM_75_1LXvl232220eRfHzHWoSakysmiBuI-Dzwq8WSoljylF9A1_Efs2695JiekEL9c0ql8Tj7SVYwpxxax-_GJJ-u4o5AfhlnEbzvdyAPwvH6W2S2Aza9vrq_vEmHMAqpFVrLtJSqsToLVQ7aK2iUMqHICo_cJFwpBUoOoazGsiH4THvs5EyXwVKwhKJBhXHIdtp5698z7pRxPmjwEqxsrCm90aQJLYCtwJqEfRm7t1703jLquMpQVb3BIGEX1PGbAuTgOp5A2OsB9vpfsCfsoIdtU81Y-fGL87eT-z6rXriQsM8jyDW-R_RzBFo_Xy9rpPKqRL0m84Qd9aBvqhC47MuFyRJWbg2HrSZs57SzX9FXd04CUkvz4X80-iN7jcBFw6FcHbOdVbf2J6iJVs2nOPyfAIPoB_g priority: 102 providerName: Directory of Open Access Journals |
| Title | The Prevalence of Epstein-Barr Virus in Normal, Premalignant, and Malignant Uterine Cervical Samples in Iran |
| URI | https://karger.com/doi/10.1159/000538734 https://www.ncbi.nlm.nih.gov/pubmed/38621370 https://www.proquest.com/docview/3039806341 https://pubmed.ncbi.nlm.nih.gov/PMC11251647 https://doaj.org/article/9a79ab01627f47f383e1279db5c4397d |
| Volume | 67 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVAON databaseName: DOAJ Directory of Open Access Journals customDbUrl: eissn: 1423-0100 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003130 issn: 0300-5526 databaseCode: DOA dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.doaj.org/ providerName: Directory of Open Access Journals – providerCode: PRVKGR databaseName: Karger Open Access Journals customDbUrl: eissn: 1423-0100 dateEnd: 99991231 omitProxy: true ssIdentifier: ssj0003130 issn: 0300-5526 databaseCode: M-- dateStart: 20210101 isFulltext: true titleUrlDefault: https://www.karger.com/OpenAccess providerName: Karger AG – providerCode: PRVPQU databaseName: Health & Medical Collection customDbUrl: eissn: 1423-0100 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0003130 issn: 0300-5526 databaseCode: 7X7 dateStart: 19950501 isFulltext: true titleUrlDefault: https://search.proquest.com/healthcomplete providerName: ProQuest – providerCode: PRVPQU databaseName: ProQuest Central customDbUrl: http://www.proquest.com/pqcentral?accountid=15518 eissn: 1423-0100 dateEnd: 20240930 omitProxy: true ssIdentifier: ssj0003130 issn: 0300-5526 databaseCode: BENPR dateStart: 19950501 isFulltext: true titleUrlDefault: https://www.proquest.com/central providerName: ProQuest |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1bb9MwFD5im0B7QVwGZIzKIB5nKYlvySOdOm1IrRCsqG-R49hbxZRWafvAv9-xc9E6wVMU3-Nz7PPZsb8D8LVKK2nzTNK0TBXljEuqdcypY8b7s9aIYv2G_nQmr-b8-0Isuv0Ofxfmjz__HKhRB24BNLjB9RzLFOMHcIQGV3mW_Cmlw5zLkuBVBDU2pli67DiE9rIewwuG-D1h3jHxIyMUuPrRALVV_wtpPj0w-cgCXb6Clx10JN9aWb-GZ7Z-A89bZ5J_38I9Spx4RiYd7hGRlSOT9cY7s6Rj3TTk97LZbciyJjMPU-_PfVp8Lm_9UZhzouuKTPtXMt-Ga4HkIkwlWOsv7WmEQ_5rNG8nML-c3Fxc0c6XAjVMSk4zLkojY5cnWlqhSyGUS-PUooFiVcYZ4g4mjMS0ztlYWuVwLZE54z0mpCXCjHdwWK9q-wFIJVRlndSWa8NLozKrpAeGRmuTa6Mi-NJ3brFuKTOKsNQQeTEII4Kx7_YhgWe5DgGr5rboBk2Ra5XrEkFpqhzHFmXMJqnKq1IYj6OqCE5aoQ3F9IWfPQm_nt20UcW6chF87kVc4GDyf0h0bVe7TYH2PM8QtPEkgvetyIciet2JINtThr1P2I-pl3eBsDvxKFJydfqf9n6EY5RFOBCUiDM43DY7-wmxzrYcwYFaqBEcjSezHz9HYcdgFFT_ATXh-YI |
| linkProvider | Karger AG |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1Lb9QwEB5BEdBLxaNAoAWDONZSEr-SI61a7UJ3L-yi3iLHsdsVVXaV3T3w7xk7D3Wr9hTF73hsz2dn_A3A9yqtpM0zSdMyVZQzLqnWMaeOGe_PWiOK9Qf6k6kczfnPK3HVnXf4uzB_vf1zoEYduAVQ4QbXcyxTjD-FZwpBt5-CE0qHNZclwasIjtiYYumy4xDayboPLxji94R5x8R3lFDg6kcF1Fb9ENK8bzB5RwNdvIKDDjqSH62sX8MTW7-B560zyX9v4RYlTjwjkw73iMjSkfPV2juzpKe6acifRbNdk0VNph6m3p74tPhcXHtTmBOi64pM-lcy34RrgeQsLCVY62_taYRD_jGqt0OYX5zPzka086VADZOS04yL0sjY5YmWVuhSCOXSOLWooFiVcYa4gwkjMa1zNpZWOdxLZM54jwlpiTDjHezVy9p-AFIJVVknteXa8NKozCrpgaHR2uTaqAi-9Z1brFrKjCJsNUReDMKI4NR3-5DAs1yHgGVzXXSTpsi1ynWJoDRVjmOLMmaTVOVVKYzHUVUEh63QhmL6wo_uhY-nszaqWFUugq-9iAucTP4Pia7tcrsuUJ_nGYI2nkTwvhX5UEQ_diLIdgbDzifsxtSLm0DYnXgUKbn6-Eh7v8DL0WxyWVyOp78-wT7KJRgHJeII9jbN1h4j7tmUn8OQ_w-C9_j2 |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=The+Prevalence+of+Epstein-Barr+Virus+in+Normal%2C+Premalignant%2C+and+Malignant+Uterine+Cervical+Samples+in+Iran&rft.jtitle=Intervirology&rft.au=Chavoshpour-Mamaghani%2C+Sara&rft.au=Shoja%2C+Zabihollah&rft.au=Jalilvand%2C+Somayeh&rft.date=2024-04-15&rft.issn=0300-5526&rft.eissn=1423-0100&rft.spage=1&rft.epage=1&rft_id=info:doi/10.1159%2F000538734&rft.externalDBID=n%2Fa&rft.externalDocID=10_1159_000538734 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0300-5526&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0300-5526&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0300-5526&client=summon |